Sponsorship
The inaugural Breast Cancer Risk Management Summit is supported by Platinum Sponsor, MyBRISK, and partner organization, InforMD. We are also delighted to welcome Lunit as a Gold Sponsor and Inherited Cancers Australia, the National Breast Cancer Foundation, and Rhythm Biosciences as Silver Sponsors.
The BRiM Summit presents a unique opportunity to explore novel personalised screening pathways that could significantly improve breast cancer outcomes. With the support of our sponsors, we aim to facilitate discussions and collaborations that can drive advancements in this area, ultimately leading to more effective and tailored screening approaches for women at varying risk levels. Our sponsors’ commitment to advancing breast cancer research and care is invaluable, and their involvement will play a crucial role in shaping the future of personalised screening strategies.
If you are an industry partner and interested in sponsoring BRiM 2026, please contact BRiMSummit-spgh@uwa.edu.au for more information.
Our Sponsors
MyBRISK is a Centre of Research Excellence funded by Australia’s National Health and Medical Research Council and combines a holistic and precision public health approach to breast cancer control. It is using artificial intelligence applied to digital mammograms, genomics, and personal and family data to stratify women across vastly different levels of breast cancer risk. Its aim is to enable more effective breast cancer screening by having it tailored to a woman’s risk level.
InforMD is a group of scientists, health professionals and community members who are dedicated to improving the detection and prevention of breast cancer through communication of risk information with the general public. Their website provides up-to-date and accurate information about breast density and breast cancer risk management, aiding translation of research evidence into clinical practice.
Lunit and Volpara have united under the Lunit name with a clear mission: to deliver a comprehensive AI-powered breast ecosystem where every insight works together. Serving over 10,000 sites across more than 65 countries, Lunit is pioneering the next era of breast health. Grounded in rigorous science and validated globally, their goal is to make AI the new standard for breast cancer risk prediction and screening, ensuring equitable access to life-saving diagnostics worldwide.
Inherited Cancers Australia is a national charity supporting, educating and advocating for Australians with inherited cancer risk. Supported by their Medical Advisory Committee, they empower people with evidence-based information so they can understand their options to manage their high cancer risk. They provide peer connection, education events, online genetic counsellor support, community catch ups and online support groups, all aimed at empowering people to manage their cancer risk.
The National Breast Cancer Foundation (NBCF) is Australia’s leading not-for-profit organisation funding world-class breast cancer research towards their vision of Zero Deaths from breast cancer. Since their inception in 1994, NBCF has invested over $250 million into more than 650 world-class research grants across Australia. Investment in research has contributed to a more than 40% reduction in the national death rate, yet there is more to be done. They know research matters, and it is central and critical to improving breast cancer outcomes. That’s why they fund the very best breast cancer research in Australia through national, competitive grant schemes and rigorous, independent expert review processes.
At Rhythm Biosciences, they believe the future of breast cancer prevention begins with identifying risk before disease develops. Through geneType®, Australia’s first NATA-accredited clinically integrated polygenic risk assessment, they are helping advance precision prevention by combining polygenic risk scores (PRS) with established clinical risk factors—including volumetric breast density, family history, age, and other key variables—to deliver clinically meaningful, individualized risk assessments. Developed through years of scientific collaboration with the late Professor John Hopper and leading clinicians and researchers from the University of Melbourne, geneType has been rigorously validated to support implementation in real-world clinical practice and population health programs. Today, Rhythm is proud to support numerous cancer risk stratification studies across Australia and the United States as the testing provider, generating the clinical evidence needed to translate precision risk assessment from research into routine care.
Together, our mission at BRiM 2026 is to bring together leading international experts in breast cancer risk management to present high-quality research, inform clinical guidance and drive change in public health policy to improve prevention and early detection of breast cancer within asymptomatic women.
